breast neoplasms/obesity

BACKGROUND Approximately 70% of newly diagnosed breast cancer patients are estrogen receptor-.alpha. positive (ER+). However, almost 50% of all ER+ breast tumors will not respond to endocrine therapy. Tamoxifen produces an overall 26% proportional reduction in mortality but many ER+ tumors that show

TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity. BACKGROUND OF THE INVENTION The estrogen

TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity. BACKGROUND OF THE INVENTION The estrogen

TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity. BACKGROUND OF THE INVENTION The estrogen

TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity. BACKGROUND OF THE INVENTION The estrogen

TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity. BACKGROUND OF THE INVENTION The estrogen

TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, as well as to pharmaceutical compositions and methods related thereto. BACKGROUND OF THE INVENTION The estrogen hormone has a broad spectrum of effects on tissues in

TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, as well as to pharmaceutical compositions and methods related thereto. BACKGROUND OF THE INVENTION The estrogen hormone has a broad spectrum of effects on tissues in

The present invention relates to novel imidazole derivatives that are used as aldosterone synthase and aromatase inhibitors, as well as for treatment of a disorder or disease mediated by aldosterone synthase or aromatase. The present invention provides a compound of formula (I) ##STR00002## wherein

The present invention relates to novel imidazole derivatives that are used as aldosterone synthase and aromatase inhibitors, as well as for treatment of a disorder or disease mediated by aldosterone synthase or aromatase. The present invention provides a compound of formula (I) ##STR00002## wherein

The present invention relates to novel imidazole derivatives that are used as aldosterone synthase and aromatase inhibitors, as well as for treatment of a disorder or disease mediated by aldosterone synthase or aromatase. The present invention provides a compound of formula (I) ##STR00002## wherein

TECHNICAL FIELD This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity, as well as to pharmaceutical compositions and methods

FIELD OF THE INVENTION The present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and for treating conditions such as cancer, arthritis, inflammatory airway disease, and metabolic disorders. More particularly, the

FIELD OF THE INVENTION The present invention is in the field of molecular biology; more particularly, the present invention describes the nucleic acid and amino acid sequences of a human, cachexia-associated protein. BACKGROUND OF THE INVENTION The characteristic wasting anorexia associated with

BACKGROUND Autosomal dominant polycystic kidney disease (ADPKD) is a frequently inherited kidney disorder with a gene frequency of 1 in 500 to 1,000 births affecting nearly 600,000 Americans and as many as 12 million people worldwide. This potentially lethal genetic disease is characterized by the